VEGFC and hydrops fetalis: To test whether cardiac lymphangiogenesis is a potential therapeutic target for the treatment of HF, WT mice were i.p. administered recombinant human VEGF‐C156S at a dose of 33 (VEGF‐C‐L) or 100 (VEGF‐C‐H) ng/g and then subjected to TAC for an additional 6 weeks (Figure 4A).